Evidence map›Paper›PMID 35534834›Full record

ArticleBMC gastroenterology2022

Anticoagulant drugs with or without proton pump inhibitor and colorectal cancer risk: a population-based, case-control study.

Pei-Huan Ho, Hung-Chun Hsiao, Chun-Wei Chen, Hui-Ming Chen, Siew-Na Lim, Chau-Ting Yeh, Chia-Jung Kuo, Wey-Ran Lin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Pei-Huan Ho *Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Hung-Chun Hsiao *Liver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Chun-Wei Chen *Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, 5, Fu-Shin Street, Taoyuan, 333, Taiwan.
Hui-Ming ChenCenter for Big Data Analytics and Statistics, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Siew-Na LimDepartment of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Chau-Ting YehLiver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Chia-Jung KuoDepartment of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, 5, Fu-Shin Street, Taoyuan, 333, Taiwan. m7011@cgmh.org.tw.
Wey-Ran LinLiver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. t12360@adm.cgmh.org.tw.
Linkou Chang Gung Memorial Hospital · TWChang Gung University · TW

Funding

Chang Gung Medical Foundation CORPG3J0501 & CORPG3J0521 & CORPG3J0531
6 · The paper itself

Abstract

backgroundLow-dose aspirin and clopidogrel have demonstrated potential chemoprevention for colorectal cancer (CRC). Proton-pump inhibitors (PPI) are commonly prescribed with anticoagulation drugs, but the relationship between PPI and CRC is unclear. Moreover, evidence of CRC risk under direct oral anticoagulant (DOAC) is limited. This study aimed to investigate the effects of anticoagulation drugs combined with or without PPI on the risks of CRC in Taiwan.

methodsA retrospective case-control study of 1,024,227 cases based on the Chang Gung Research Database from 2010 to 2017 was performed. Clinical characteristics, indications, duration of anticoagulation and PPI use, and CRC occurrence data were collected. Logistic regression was employed to adjust for known confounders of CRC risk.

resultsMonotherapy of clopidogrel decreased the risk of CRC (AOR 0.70; 95% CI 0.60-0.83), while no protective effect was observed in aspirin alone or aspirin plus clopidogrel. DOAC did not affect CRC significantly. The risk of CRC increased in patients with PPI (AOR 1.38; 95% CI 1.28-1.49) and PPI plus DOAC (OR 3.91; 95% CI 1.49-10.27), while PPI plus aspirin decreased the risk of CRC (OR 0.48; 95% CI 0.32-0.73). PPI plus clopidogrel showed no significant effect on the CRC.

conclusionThis study suggests clopidogrel alone and PPI plus aspirin offer a preventative benefit against CRC in the Taiwanese population studied. The same effect was not observed in DOAC. Moreover, a significant increase in CRC was observed in patients on PPI monotherapy and PPI plus DOAC, suggesting a possible risk.

Indexed as

Colorectal NeoplasmsProton Pump InhibitorsAnticoagulantsAspirinCase-Control StudiesClopidogrelDrug Therapy, CombinationHumansPlatelet Aggregation InhibitorsRetrospective StudiesAnticoagulantsAspirinClopidogrelPlatelet Aggregation InhibitorsProton Pump InhibitorsClopidogrelColorectal cancerDirect oral anticoagulantLow-dose aspirinProton pump inhibitor

Identifiers

PMID35534834
PMCPMC9082832
OpenAlexW4229364059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.